IGC Pharma, Inc. (IGC) company profile

IGC Pharma, Inc. is a clinical-stage biotechnology company focused on developing therapies to treat and diagnose central nervous system disorders, primarily Alzheimer’s disease. The company operates in a single reportable segment, Life Sciences, having previously realigned away from its legacy Infrastructure activities. Its product pipeline centers on innovative drug candidates targeting neurodegenerative conditions, notably its lead candidate IGC-AD1, which is undergoing clinical evaluation for agitation associated with Alzheimer’s dementia. Additionally, the company advances preclinical therapeutic candidates targeting amyloid-beta plaque formation and metabolic disorders, while applying artificial intelligence and machine learning models to identify early diagnostic markers and optimize clinical trials.

The company is incorporated in Maryland and maintains its principal executive offices in Potomac, Maryland. It conducts clinical and developmental activities across North America, including clinical trial sites in the United States and Canada, and harmonizes longitudinal and clinical research databases representing international participants across the Americas and Asia.

Summary of the business section of IGC Pharma's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of March 31, 2024, we employed a team of approximately 67 full-time employees in our two segments.”